Search Results

PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the Clinical Psychedelic Lab at Monash University’s upcoming Phase 2 Clinical Trial.

Cryoport, Inc. announced that the Company has signed a new three-year supply chain solutions agreement with Monash IVF Group Limited, a leading provider of assisted reproductive services, as well as specialist women’s imaging and diagnostic services in Australia and Southeast Asia.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Today, Integral Biosciences Pvt Ltd (IBS) and Monash University (Monash) have announced a research collaboration to discover small molecule therapeutics.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

DepYmed, Inc. (“DepYmed” or the “Company”) and the Monash Biomedicine Discovery Institute (“Monash BDI”) at Monash University in Melbourne, Australia announce today that they have entered into a sponsored research agreement (SRA) to explore the potential of the Company’s drug development candidates to treat cancer by targeting a newly discovered intracellular immune checkpoint.

Pfizer is proud to announce that it is supporting a McMaster University-led study, through the Ontario Clinical Oncology Group, that aims to improve care for Canadians living with multiple myeloma.

University Cancer & Blood Center, a leading oncology and hematology practice for Northeast Georgia, and University Health Alliance, a multi-disciplinary practice focusing on prevention and coordinated care, announce the opening of their High-Risk GI Clinic.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

The Feinstein Institutes for Medical Research has selected Michelle Monje, MD, PhD, from Stanford University, to receive the 11th annual Ross Prize in Molecular Medicine for her outstanding contributions to research relating to the neuroscience of cancer and its implications for therapy.